BTIG analyst Jeet Mukherjee initiated coverage of Kymera Therapeutics (KYMR) with a Buy rating and $60 price target The company is a differentiated player in the degrader field going after immunology & inflammation targets where removal of critical proteins and their scaffolding function could provide greater efficacy that better reflects biologics rather than small molecule inhibitors, the analyst tells investors in a research note. BTIG adds that it sees STAT6 degrader, KT-621, having the potential for Dupixent-like efficacy, with Phase 1 HV data coming in the first half of FY25, while Kymera’s TYK2 degrader KT-295 could differentiate from TYK2 inhibitors, with Phase 1 data coming in the second half of FY25.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics initiated with a Market Perform at BMO Capital
- Kymera Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- Kymera Therapeutics initiated with an Overweight at Stephens
- Kymera Therapeutics price target raised to $49 from $45 at Morgan Stanley
- Kymera Therapeutics price target raised to $52 from $45 at Guggenheim